Publications by authors named "Lea M Stitzlein"
Background: Diffuse intrinsic pontine glioma (DIPG) carries a poor prognosis with a median survival of less than 12 months. Key molecular features include histone H3 mutation (K27M) and AKT pathway dysregulation. There is currently no curative treatment.
View Article and Find Full Text PDFImpact of electronic cigarettes on pediatric, adolescent and young adult leukemia patients.
Pediatr Med
February 2024
Electronic cigarettes, which deliver an aerosolized, nicotine-containing product upon inhalation, are a public health issue that continue to gain popularity among adolescents and young adults in the United States. Use of electronic cigarettes is wide, and extends to pediatric patients with multiple comorbidities, including childhood cancer, leaving them vulnerable to further negative health outcomes. Acute leukemias are the most common type of cancer in pediatric populations, and treatment outcomes for these patients are improving; consequently, there is an increased emphasis on the effect of behavioral lifestyle factors on quality of life in survivorship.
View Article and Find Full Text PDFCase series: Stenotrophomonas maltophilia in pediatric oncology patients.
Cancer Rep (Hoboken)
March 2024
Background: Stenotrophomonas maltophilia is a bacterial pathogen that can be fatal in hospitalized and immunocompromised patients with mortality as high as 69%. Pediatric cancer patients often have risk factors that are common for this infection, making them particularly susceptible. Managing S.
View Article and Find Full Text PDFArticle Synopsis
- Targeted therapies, such as small molecule inhibitors for aberrant kinase signaling and chromatin regulators, show promise in treating high-grade gliomas (HGG), but typically result in only temporary responses.
- Recent research highlights the collaboration between epigenetic regulators and kinase signaling networks, which contributes to the aggressive nature of the gliomas and their resistance to treatment.
- This review focuses on five key chromatin regulators with potential for pharmacological targeting, emphasizing that combining the inhibition of these regulators with kinase signaling could enhance treatment effectiveness in HGG, improving patient outcomes.
Article Synopsis
- Improved glioblastoma (GBM) therapies are needed, with a focus on evaluating LSD1 inhibitors in models that reflect patient tumor diversity and resistance.
- Researchers conducted RNA-seq to explore the effects of LSD1 knockdown and inhibition in patient-derived GBM stem cell lines and mouse models, leading to the identification of genes related to treatment resistance.
- Findings suggest that LSD1 inhibitors can delay tumor growth, and identifying resistance-associated genes may help develop more effective combination treatments in the future.
Design, synthesis, and biological evaluation of lipophilically modified bisphenol Z derivatives.
Chem Biol Drug Des
August 2019
In the present study, a small library of bisphenol Z (BPZ) derivatives was synthesized and investigated for anti-proliferative effects in cultured breast and glioblastoma cell lines. Synthesized BPZ derivatives varied in molecular size, polarity, and lipophilicity. Of the 8 derivatives tested, compounds 4 and 6, both of which displayed the highest degree of lipophilicity, were most active at inducing cell death as determined by the XTT assay.
View Article and Find Full Text PDF